Milestone Scientific Inc.: Form 10-Q for the period ended Jun 30, 2018
Filed with the SEC on Aug 14, 2018 and accepted by EDGAR at Aug 14, 2018, 16:25 ET.
Management's discussion and analysis
As filed, 25,919 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.
OVERVIEW
Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, dental, cosmetic and veterinary applications. Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies and solutions for the medical and dental markets. We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection systems make injections precise, efficient and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.
Milestone Scientific remains focused on advancing efforts to achieve the following five primary objectives:
- Establishing Milestone’s DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first-time objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;
- Following obtaining successful FDA clearance of our first medical device in June 2017, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company;
- Commercializing our CompuFlo Epidural System, a transformative device for epidural anesthesia procedures;
- Expanding the global footprint of our CompuFlo Epidural System by partnering with distribution companies worldwide; and
- Obtaining regulatory approval of our proprietary cosmetic injection device for delivery of botulinum toxin (such as Botox® and Dysport®) and the commercial launch.
Distribution and Marketing Arrangements
Our dental devices are sold in the United States, Canada, and in over 53 countries abroad. In June 2017, we received FDA regulatory clearance to sell our first medical device, the CompuFlo Epidural System in the United States. Since receiving FDA clearance in 2017 our epidural devices have had minimal sales in the United States and Europe.
Dental Market
In the spring of 2009, Milestone Scientific signed a distribution and marketing agreement with China National Medicines Corporation, dba Sinopharm. In early October 2012, the State Food and Drug Administration (“CFDA”) of the People’s Republic of China approved the Wand STA System. However, the CFDA’s approval of the Wand STA handpieces was not received until May 2014 and the distribution of these handpieces in China began in the fourth quarter of 2014. The distribution and marketing agreement with Sinopharm were terminated in September 2014. Proximate to that time, we entered into a new agreement with Milestone China to be our distributor for the Wand STA System and handpieces in China.
In November 2012, Milestone Scientific signed an exclusive distributor and marketing agreement with a well-known U.S. domestic manufacturer and distributor, for the sale and distribution of the Wand STA System and handpieces in the United States and Canada. The marketing initiative included participation in United States and Canadian dental shows, as well as pediatric dental shows; an active advertising initiative targeting major dental publications;
and direct mailing campaigns to over 150,000 dentists across the United States and Canada. This exclusive distributor and marketing agreement were converted to a non-exclusive agreement as of December 31, 2016.
Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein. In June 2016, that agreement was replaced by a new agreement with Henry Schein providing for an exclusive distribution arrangement for our dental products in the United States and Canada by a newly formed marketing and sales group at Henry Schein. Under this arrangement, we have a semi-dedicated independent sales force visiting dentists. Henry Schein’s exclusive products sales specialist team, which is comprised of 25 sales representatives and supported by over 1,000 field service representatives, will exclusively market and distribute the Wand STA System and handpieces, together with a select group of other devices in the United States and Canada. Our agreement with Henry Schein has minimum purchase orders to maintain exclusivity in the third through tenth years. We believe that this exclusive arrangement will be more effective than previous arrangements relying on Wand Dental's appearances at dental shows and catalog sales.
Medical Market
Having received FDA clearance to sell the CompuFlo Epidural System in June 2017, we are in discussions with a small number of regional and national distributors. Our immediate focus is on marketing our epidural device in the U.S. and throughout Europe.
In February and March 2018, Milestone Scientific hired an Executive VP of Global Sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System.
We have entered into a limited number of distributor arrangements in Europe and the Middle East for our CompuFlo Epidural Computer Controlled Anesthesia System. Our distribution strategy is initially aimed at having Key Opinion Leaders (KOL) use and accept the device and initiate their own studies. This having been accomplished we are now placing devices in key institutions.
The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category for three months ended June 30, 2018 and 2017, respectively:
| Domestic US / Canada: | Three months ended June 30, 2018 Dental | Medical | Total | 2017 Dental | Medical | Total |
|---|---|---|---|---|---|---|
| Device | $11,505 | $- | $11,505 | $219,648 | $- | $219,648 |
| Handpieces | 1,158,975 | - | 1,158,975 | 1,182,985 | - | 1,182,985 |
| Other | 22,377 | - | 22,377 | 21,509 | - | 21,509 |
| Total Domestic US / Canada | 1,192,857 | - | 1,192,857 | 1,424,142 | - | 1,424,142 |
| International Rest of the World: | ||||||
| Device | 329,450 | 38,000 | 367,450 | 353,805 | - | 353,805 |
| Handpieces | 839,194 | - | 839,194 | 362,437 | - | 362,437 |
| Other | 27,397 | 1,600 | 28,997 | 26,966 | - | 26,966 |
| Total International Rest of the World | 1,196,041 | 39,600 | 1,235,641 | 743,208 | - | 743,208 |
| International China: | ||||||
| Device | - | - | - | - | - | - |
| Handpieces | - | - | - | 356,400 | - | 356,400 |
| Other | - | - | - | - | - | - |
| Total International China | - | - | - | 356,400 | - | 356,400 |
| Total Product Sales | $2,388,898 | $39,600 | $2,428,498 | $2,523,750 | $- | $2,523,750 |
22
The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category for six months ended June 30, 2018 and 2017, respectively:
| Domestic US / Canada: | Six months ended June 30, 2018 Dental | Medical | Total | 2017 Dental | Medical | Total |
|---|---|---|---|---|---|---|
| Device | $132,553 | $- | $132,553 | $405,293 | $- | $405,293 |
| Handpieces | 1,927,506 | - | 1,927,506 | 2,693,471 | - | 2,693,471 |
| Other | 51,228 | - | 51,228 | 40,449 | - | 40,449 |
| Total Domestic US / Canada | 2,111,287 | - | 2,111,287 | 3,139,213 | - | 3,139,213 |
| International Rest of the World: | ||||||
| Device | 576,418 | 70,500 | 646,918 | 712,475 | - | 712,475 |
| Handpieces | 1,418,021 | - | 1,418,021 | 945,786 | - | 945,786 |
| Other | 52,277 | 5,600 | 57,877 | 57,064 | - | 57,064 |
| Total International Rest of the World | 2,046,716 | 76,100 | 2,122,816 | 1,715,325 | - | 1,715,325 |
| International China: | ||||||
| Device | - | - | - | 1,000,000 | - | 1,000,000 |
| Handpieces | - | - | - | 356,400 | - | 356,400 |
| Other | - | - | - | 1,800 | - | 1,800 |
| Total International China | - | - | - | 1,358,200 | - | 1,358,200 |
| Total Product Sales | $4,158,003 | $76,100 | $4,234,103 | $6,212,738 | $- | $6,212,738 |
Milestone Scientific plans to support increased sales and marketing activity through our current distributors and through newly appointed distributors of the Wand STA devices and handpieces in the international market. In the United States and Canada, Milestone Scientific will continue the utilization of independent hygienists for training individual practitioners and group practices domestically, refined and directed advertising to dental professionals, continue to develop Key Opinion Leaders (KOL) and support and broaden our global distribution network. Additionally, with the recent FDA marketing clearance for the CompuFlo Epidural System, Milestone Scientific is initiating marketing and sales efforts in the U.S. to establish medical sector distributors for the sale of this device.
Current Product Platform
See Item 1. Description of Business.
Results of Operations
The following table sets forth for the consolidated results of operations for the three months ended June 30, 2018 compared to 2017 as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results:
| Operating results: | For three months ended June 30, 2018 | 2017 | ||
|---|---|---|---|---|
| Product sales, net | $2,428,498 | 100% | $2,523,750 | 100% |
| Cost of products sold | 1,021,573 | 42% | 873,586 | 35% |
| Gross Profit | 1,406,925 | 58% | 1,650,164 | 65% |
| Operating expenses: | ||||
| Selling, general, and administrative | 2,821,837 | 116% | 3,082,534 | 122% |
| Research & development | 9,775 | 0% | 120,065 | 5% |
| Operating Loss | (1,424,687) | -59% | (1,552,435) | -62% |
| Other Income, net | 74,686 | 3% | 11,926 | 0% |
| Net Loss | (1,350,001) | -56% | (1,540,509) | -61% |
| Net loss profit attributable to noncontrolling interest | 6,994 | 0% | 61,684 | 2% |
| Net loss attributable to Milestone Scientific Inc. | $(1,343,007) | -55% | $(1,478,825) | -59% |
The following table sets forth for the consolidated results of operations for the six months ended June 30, 2018 compared to 2017 as a percentage of product sales, net. The trends suggested by this table may not be indicative of future operating results:
| Operating results: | For six months ended June 30, 2018 | 2017 | ||
|---|---|---|---|---|
| Product sales, net | $4,234,103 | 100% | $6,212,738 | 100% |
| Cost of products sold | 1,584,250 | 37% | 2,275,871 | 37% |
| Gross Profit | 2,649,853 | 63% | 3,936,867 | 63% |
| Operating expenses: | ||||
| Selling, general, and administrative | 5,840,601 | 138% | 5,790,161 | 93% |
| Research & development | 235,592 | 6% | 225,080 | 4% |
| Operating Loss | (3,426,340) | -79% | (2,078,374) | -33% |
| Other Income, (expenses), net | 100,969 | 2% | (40,127) | -1% |
| Net Loss | (3,325,371) | -78% | (2,118,501) | -34% |
| Net loss profit attributable to noncontrolling interest | 108,657 | 3% | 134,808 | 2% |
| Net loss attributable to Milestone Scientific Inc. | $(3,216,714) | -76% | $(1,983,693) | -32% |
| Cash flow: | For six months ended June 30, 2018 | 2017 |
|---|---|---|
| Net cash used in operating activities | $(1,516,771) | $(952,386) |
| Net cash used in investing activities | $(4,531) | $(42,548) |
| Net cash provided by financing activities | $(250,000) | $338,336 |
Three Months ended June 30, 2018 compared to Three Months ended June 30, 2017
Net sales for three months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $2,388,898 | $2,523,750 | $(134,852) | -5.34% |
| Medical | 39,600 | - | 39,600 | -100.00% |
| Total | $2,428,498 | $2,523,750 | $(95,252) | -3.77% |
Consolidated revenue for the three months ended June 30, 2018 and 2017 were approximately $2.4 million and $2.5 million, respectively. Dental revenue for the three months ended June 30, 2018 and 2017 were approximately $2.4 million and $2.5 million, respectively. Domestic dental revenue decreased approximately $231,000 during the three months ended June 2018, compared to 2017. The decrease in domestic revenue is related to Henry Schein selling through the inventory purchased in the fourth quarter of 2017 to avoid a price increase effective in the first quarter of 2018.
International dental revenue increased approximately $453,000 for the three months ended June 2018 compared to 2017. The increase in international dental revenue is due to a sale of instruments and handpieces on a government grant in Mexico for approximately $382,000. China revenue decreased for three months ended June 30, 2018 by approximately $356,000. Milestone China is working through inventory purchases from 2017 and making modifications to their business strategy to better serve the Chinese dental market.
Gross Profit (loss) for three months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $1,613,059 | $1,650,164 | $(37,105) | -2.25% |
| Medical | (206,134) | - | (206,134) | 100% |
| Total | $1,406,925 | $1,650,164 | $(243,239) | -14.74% |
Consolidated gross profit for the three months ended June 30, 2018 and 2017 were approximately 58% and 65%, respectively. The decrease in gross profit percentage for the three months ended June 30, 2018 is due to an increase allowance for slow moving inventory of approximately $290,000 during the three months ended June 30, 2018.
Selling, general and administrative expenses for three months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $957,464 | $1,089,777 | $(132,313) | -12.14% |
| Medical | 630,254 | 539,065 | 91,189 | 16.92% |
| Corporate | 1,234,119 | 1,453,699 | (219,580) | -15.10% |
| Total | $2,821,837 | $3,082,541 | $(260,704) | -8.46% |
Consolidated selling, general and administrative expenses for the three months ended June 30, 2018 and 2017 were approximately $2.8 million and $3.1 million, respectively. The decrease of $261,000 is primarily related to a decrease in in professional fees, travel expense, and employee related expenses of approximately $420,000, offset by an increase in amortization of the patents acquired in the APAD purchase in 2017 of approximately $213,000.
Research and Development for three months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $- | $- | $- | 0.00% |
| Medical | 9,775 | 65,065 | (55,290) | -84.98% |
| Corporate | - | 55,000 | (55,000) | -100.00% |
| Total | $9,775 | $120,065 | $(110,290) | -91.86% |
Consolidated research and development expenses for the three months ended June 30, 2018 and 2017 were approximately $10,000 and $120,000, respectively. The decrease is due a delay in the development of the cosmetic injection device during the second quarter of 2018.
Profit (Loss) from Operations for three months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $723,084 | $540,061 | $183,023 | 33.89% |
| Medical | (846,164) | (604,130) | (242,034) | 40.06% |
| Corporate | (1,301,607) | (1,488,366) | 186,759 | -12.55% |
| Total | $(1,424,687) | $(1,552,435) | $127,748 | -8.23% |
The loss from operations for the three months ended June 30, 2018 and 2017 was approximately $1.4 million and $ 1.6 million, respectively, a decrease of approximately $128,000.The dental segment of the business is controlling expenses for a mature market. The medical segment is increasing cost as personnel is expanded in the USA to increase our domestic Epidural instrument business
Six Months ended June 30, 2018 compared to Six Months ended June 30, 2017
Net sales for six months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $4,158,003 | $6,212,738 | $(2,054,735) | -33.07% |
| Medical | 76,100 | - | 76,100 | 100.00% |
| Total | $4,234,103 | $6,212,738 | $(1,978,635) | -33.07% |
Consolidated revenue for the six months ended June 30, 2018 and 2017 were approximately $4.2 million and $6.2 million, respectively. Dental revenue for the six months ended June 30, 2018 and 2017 were approximately $4.2 million and $6.2 million, respectively. Domestic dental revenue decreased approximately $2.1 million during the six months ended June 2018, compared to 2017. The decrease in domestic revenue of approximately $ 1 million is related to Henry Schein working through the inventory purchased in the fourth quarter of 2017 to avoid a price increase effective in the first quarter of 2018. International dental revenue increased approximately $331,000 for the six months ended June 2018 compared to 2017. The increase in international dental revenue is due to a sale of instruments and handpieces on a government grant in Mexico for approximately $382,000. China revenue decrease for six months ended June 30, 2018 by approximately $1.3 million. Milestone China is working through inventory purchases from 2017 and making modifications to their business strategy to better serve the China dental market.
Gross Profit (loss) for six months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $2,831,085 | $3,936,867 | $(1,105,782) | -28.09% |
| Medical | (181,232) | - | (181,232) | -100% |
| Total | $2,649,853 | $3,936,867 | $(1,287,014) | -32.69% |
Consolidated gross profit for the six months ended June 30, 2018 and 2017 were approximately 63%, respectively. Although the gross margin percentage remained at 63%, gross profit dollars in 2018 decreased to approximately $2.6 million from approximately $3.9 million in 2017, or by approximately $1.3 million over the same period year over year. The gross profit percentage for the six months ended June 30, 2018 would have been approximately $1.9 million without the allowance for slow moving inventory. This $1.9 million in gross profit would have resulted in a gross profit of 68.6%. This increase in gross margin is due to no sales from our lower margin distributor during six months ended June 30, 2018.
Selling, general and administrative expenses for six months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $1,818,325 | $2,097,848 | $(279,523) | -13.32% |
| Medical | 1,308,306 | 1,128,548 | 179,758 | 15.93% |
| Corporate | 2,713,970 | 2,563,765 | 150,205 | 5.86% |
| Total | $5,840,601 | $5,790,161 | $50,440 | 0.87% |
Consolidated selling, general and administrative expenses for the six months ended June 30, 2018 and 2017 were approximately $5.8 million respectively. The increase of $50,000 is primarily related to an increase in amortization of the patents acquired in the APAD purchase in 2017 of approximately $443,000, offset by a decrease in in professional fees, travel expense, and employee related expenses of approximately $393,000.
Research and Development for six months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $- | $3,000 | $(3,000) | 100.00% |
| Medical | 65,008 | 99,909 | (34,901) | -34.93% |
| Corporate | 170,584 | 122,171 | 48,413 | 39.63% |
| Total | $235,592 | $225,080 | $10,512 | 4.67% |
Consolidated research and development expenses for the six months ended June 30, 2018 and 2017 were approximately $235,000 and $225,000, respectively. The decrease is due a delay in the development of the cosmetic injection device during the second quarter of 2018.
Profit (Loss) from Operations for six months ended June 30, 2018 and 2017 were as follows:
| 2018 | 2017 | Increase (Decrease) $% | ||
|---|---|---|---|---|
| Dental | $1,080,249 | $1,973,249 | $(893,000) | -45.26% |
| Medical | (1,554,546) | (1,228,457) | 326,089 | -26.54% |
| Corporate | (2,952,043) | (2,823,166) | (128,877) | 4.56% |
| Total | $(3,426,340) | $(2,078,374) | $(1,347,966) | 64.86% |
The loss from operations for the six months ended June 30, 2018 and 2017 was approximately $3.4 million and 2.1, respectively, an increase of approximately $1.3 million. This increase is primarily attributable to the reduction in net sales of $1.3 million, and increase in selling, general and administrative of $50,000 as explained above.
Liquidity and Capital Resources
At June 30, 2018, Milestone Scientific had cash and cash equivalents of approximately $0.9 million, total current assets of approximately $11 million and working capital of approximately $2.8 million. We believe that our cash on hand, collection of accounts receivable and the anticipated revenues from the dental business will be sufficient to fund our business operations for at least the next 12 months from the filing date of this Form 10-Q. However, should the Company's sales performance, selling expenditures for the U.S. Epidural medical device launch, issues collecting the China affiliate receivable and the new product development programs deviate from Managements’ plan, the Company may not be able to meet its anticipated obligations over the next twelve months from the financial reporting date. Significant deviations, together with limitations on funding could require a delay, scale back or elimination of some or all of the Company’s development programs which could have a material adverse impact on the company.
Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. The capital raised in December 2016 and January 2017 provided Milestone Scientific with working capital to continue to develop its medical devices and obtain FDA regulatory clearance of its CompuFlo Epidural System, as well as to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide and a reduction in operating expenses.
Now that the CompuFlo Epidural System has obtained FDA clearance in the United States, the Company’s development costs should be lower in 2018. The FDA clearance will provide the Company with the opportunity to establish distribution in the USA. At the same time, the Company is looking to establish additional financing opportunities to help with the commercialization of the Epidural device. In June 2018, Milestone Scientific filed a new 510(k) application for its intra-articular device. Most of the cost associated with this application were internal personnel cost and some low level third party review expense.
Milestone Scientific believes that the FDA clearance of its 510(k) applications with respect to the CompuFlo Epidural System will provide Milestone Scientific with the opportunity to enter the US medical device market and generate revenues in the future. Milestone Scientific believes that it has sufficient inventory of epidural devices to satisfy the near-term marketing opportunities.
In February and March 2018 Milestone Scientific hired an Executive VP of Global sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System.
Milestone Scientific believes that the exclusive distribution agreement with Henry Schein will continue to improve its domestic revenues in 2018. To further reduce Milestone Scientific's expenditures, Milestone Medical is carefully managing expenses related to obtaining FDA clearance for the intra-articular devices.
Our condensed consolidated balance sheets included in this Quarterly Report reflect a decrease of approximately $1 million in current assets from December 31, 2017 to June 30, 2018. This decrease in current assets was primarily due to a reduction in cash, notes receivable, and inventory of approximately $3.3 million. This was offset by increases in accounts receivable and advances on contracts of an aggregate of approximately $2.2 million.
In this Quarterly Report our consolidated balance sheets included an increase in current liabilities of approximately $1.4 million from approximately $6.7 million to approximately $8.1 million. This increase is primarily due to a decrease in accrued expenses and deferred profit related party of approximately $466,000 offset by an increase in accounts payable, accounts payable related party, deferred revenue related party of approximately $1.8 million.
Market risk
As filed, 162 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.
Controls and procedures
As filed, 1,311 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of June 30, 2018 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in Milestone Scientific’s internal control over financial reporting that occurred during Milestone Scientific’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-04-01 to 2018-06-30 | $2.4m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2018-01-01 to 2018-06-30 | $4.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2018-04-01 to 2018-06-30 | $1.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2018-01-01 to 2018-06-30 | $1.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2018-04-01 to 2018-06-30 | $1.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2018-01-01 to 2018-06-30 | $2.6m | us-gaap:GrossProfit |
| Research and development | 3 months2018-04-01 to 2018-06-30 | $9.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2018-01-01 to 2018-06-30 | $235.6k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-04-01 to 2018-06-30 | $2.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2018-01-01 to 2018-06-30 | $5.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-04-01 to 2018-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-01-01 to 2018-06-30 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2018-04-01 to 2018-06-30 | $4.1k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2018-01-01 to 2018-06-30 | $15.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-04-01 to 2018-06-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2018-01-01 to 2018-06-30 | −$3.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-04-01 to 2018-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2018-01-01 to 2018-06-30 | −$0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-04-01 to 2018-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2018-01-01 to 2018-06-30 | −$0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-04-01 to 2018-06-30 | 35,297,906 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2018-01-01 to 2018-06-30 | 34,939,306 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2018-01-01 to 2018-06-30 | −$1.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2018-06-30 | $865.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-06-30 | $11.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-06-30 | $13.4m | us-gaap:Assets |
| Current liabilities | At period end2018-06-30 | $8.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-06-30 | $8.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-06-30 | $5.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-18-015605. Last ingested by Listed: Nov 14, 2026, 11:14 ET. Listed shows no prices and gives no investment advice.